STOCK TITAN

Delcath Systems (DCTH) Stock News

DCTH NASDAQ

Delcath Systems, Inc. develops interventional oncology products for primary and metastatic liver cancers. Its core products include HEPZATO KIT, a melphalan and Hepatic Delivery System combination product approved in the United States as a liver-directed treatment for adult patients with metastatic uveal melanoma, and CHEMOSAT Hepatic Delivery System for Melphalan used in percutaneous hepatic perfusion.

Recurring news covers quarterly operating results, HEPZATO KIT and CHEMOSAT revenue, clinical publications from studies such as FOCUS and CHOPIN, presentations at oncology and interventional radiology meetings, guideline recognition, and studies of melphalan-based percutaneous hepatic perfusion in liver-dominant cancers. Company updates also address FDA-approved product status, European clinical practice references, and capital actions such as common-stock repurchases.

Rhea-AI Summary

Delcath Systems (Nasdaq: DCTH) granted restricted stock units covering 21,250 common shares as employment inducements to three individuals. The awards fall under the 2023 Inducement Plan and Nasdaq Listing Rule 5635(c)(4). One-third of the units vest on the first anniversary of the grant date, with the remaining two-thirds vesting in equal annual installments over the following two years, subject to continued employment on each vesting date.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Delcath Systems (DCTH) will be featured on Health Uncensored with Dr. Drew, scheduled to air nationally on November 15, 2026. The segment, titled “Precision Oncology: Changing the Game for Metastatic Liver Cancer,” is scheduled for 5:30 p.m. ET / 2:30 p.m. PT on FOX Business Network.

The program discusses percutaneous hepatic perfusion, a procedure that delivers chemotherapy directly to the liver while filtering blood before returning it to circulation. It features Delcath CEO Gerard Michel and Dr. Sachin Modi of University Hospital Southampton. A podcast is expected following the broadcast, and episodes are also available afterward on the program’s website and YouTube channel.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.79%
Tags
none
-
Rhea-AI Summary

Delcath Systems (DCTH) raised its 2026 revenue guidance to $115 million–$117 million while reporting higher third-quarter revenue and net income. Revenue reached $35.1 million, versus $20.6 million a year earlier, including $32.7 million from HEPZATO KIT and $2.4 million from CHEMOSAT. Net income rose to $7.0 million from $0.8 million, and diluted earnings per share increased to $0.17 from $0.02. Gross margin improved to 89% from 87%.

Operating cash flow was $8.2 million, versus $4.8 million. Cash and investments totaled $104.3 million at September 30, with no debt. Research and development and selling expenses increased. Delcath expects full-year gross margins of 87%–89% and positive adjusted EBITDA, an adjusted earnings measure. The Phase 2 DELUMA trial dosed its first patient on July 9, 2026; Delcath also plans a cholangiocarcinoma investigational drug application in early 2027.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
35.77%
Tags
Rhea-AI Summary

Delcath Systems (Nasdaq: DCTH) announced that management will attend the UBS Global Healthcare Conference on November 10, 2026.

The conference is in Palm Beach Gardens, Florida. Management will also attend Canaccord Genuity's MedTech, Diagnostics and Digital Health & Services Forum on November 11 and the Craig-Hallum Alpha Select Conference on November 17, both in New York. A live and archived UBS webcast will be available at investors.delcath.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.65%
Tags
conferences
-
Rhea-AI Summary

Delcath Systems (DCTH) will host its third-quarter 2026 earnings conference call on November 9, 2026, at 8:30 AM Eastern Time. The call will discuss results for the quarter ended September 30, 2026. A replay will be available shortly after the call concludes and archived on the company's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.62%
Tags
earnings date
-
Rhea-AI Summary

Delcath Systems (DCTH) highlighted clinical program presentations at ESMO Congress 2026 and an independent analysis of CHEMOSAT hepatic perfusion.

The congress runs October 23–27 in Madrid, with updates on Phase 2 breast and colorectal cancer trials. The independent retrospective analysis covered 12 patients with liver-dominant metastatic uveal melanoma, an eye cancer that had spread mainly to the liver. Objective response was 66.7% and disease control was 75%. Median time without liver disease progression was 18.4 months; median overall survival was 28 months. Serious adverse events occurred in three patients, with no treatment-related deaths. Exploratory analyses associated BAP1 loss and monosomy 3 with shorter survival.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.71%
Tags
none
Rhea-AI Summary

Delcath Systems (DCTH) granted equity awards as material inducements to four employees whose employment began in July or August 2026. The awards consist of 34,000 restricted stock units (RSUs) of common stock granted on September 1, 2026 under the company’s 2023 Inducement Plan. One-third of the RSUs vest on the first anniversary of the grant date and the remaining two-thirds vest in equal annual installments over the following two years, subject to continued employment, in accordance with Nasdaq Listing Rule 5635(c)(4).

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.33%
Tags
none
-
Rhea-AI Summary

Delcath Systems (Nasdaq: DCTH), an interventional oncology company focused on primary and metastatic liver cancers, announced that its management will attend two investor events: the Wells Fargo Healthcare Conference on September 10, 2026, in Boston, MA, and the H.C. Wainwright 27th Annual Global Investment Conference on September 15, 2026, in New York, NY.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.36%
Tags
conferences
-
Rhea-AI Summary

Delcath Systems (Nasdaq:DCTH) reported second quarter 2026 revenue of $29.1M, up from $24.2M in 2025, driven by HEPZATO KIT $27.1M and CHEMOSAT $2.0M. Gross margin rose to 90%. Net income was $2.7M, flat year over year, while non-GAAP adjusted EBITDA declined to $7.6M from $9.8M. Operating cash flow was $5.7M, and cash and investments totaled $95.9M with no debt at June 30, 2026.

The company now guides 2026 revenue to $104M–$108M, implying at least 28% HEPZATO KIT volume growth, full-year gross margin of 86%–89%, and positive adjusted EBITDA. Delcath highlighted 31 active treatment centers, ~30% HEPZATO volume growth, new investigator-initiated combination trials in melanoma, and first dosing in a global Phase 2 study in liver-dominant HER2-negative metastatic breast cancer.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
22.49%
Tags
Rhea-AI Summary

Delcath Systems (Nasdaq: DCTH) announced that its management will attend the Canaccord Genuity 46th Annual Growth Conference on Tuesday, August 11, 2026, in Boston, MA. Delcath is an interventional oncology company focused on treating primary and metastatic cancers of the liver.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.26%
Tags
none

FAQ

What is the current stock price of Delcath Systems (DCTH)?

Delcath Systems (DCTH) last closed at $19.87.

What is the market cap of Delcath Systems (DCTH)?

The market cap of Delcath Systems (DCTH) is approximately $691.2M.